Aman 🧙‍♂️

744 posts

Aman 🧙‍♂️ banner
Aman 🧙‍♂️

Aman 🧙‍♂️

@amanwon

Founder and developer https://t.co/zh4AXX0loA, https://t.co/pPYgFFPxKh college dropout turned entrepreneur.

california Sumali Ağustos 2020
270 Sinusundan126 Mga Tagasunod
Naka-pin na Tweet
Aman 🧙‍♂️
Aman 🧙‍♂️@amanwon·
1. How I used improv as a playground to socially fail and what I learned so you can become an unstoppable charismatic attractive genuinely cool person (insert more adjectives...) 🧵 👇👇👇
English
1
2
11
0
Kamal Razzak
Kamal Razzak@kamal_razzak·
My UGC/AFF/CREATOR/INFLUENCER/SEEDING tool is ready for beta testers HMU in DMs or reply below and I'll send a loom showing you how it works If you wanna 100x your capacity, reduce costs by 90% - this is the tool all the other tools on the market do not compare
English
191
2
137
44.9K
Aman 🧙‍♂️ nag-retweet
Aman 🧙‍♂️ nag-retweet
Melodies & Masterpieces
Melodies & Masterpieces@SVG__Collection·
“First you imitate, then you innovate.” — Miles Davis
Melodies & Masterpieces tweet media
English
23
855
4.3K
74.6K
Kalsoom Lakhani
Kalsoom Lakhani@kalsoom82·
Between Pakistan mediating talks between the U.S. and Iran, Riz Ahmed's incredible show Bait on Amazon Prime (w/ amaaazing music by the likes of @arooj_aftab & @rukhsanakartoos) & now the potential acquisition of Cursor by SpaceX for $60B, a company co-founded by Pakistani Sualeh Asif, what a good time to be Pakistani 🥲🇵🇰 dawn.com/news/1994327
English
20
59
369
26.3K
Aman 🧙‍♂️
Aman 🧙‍♂️@amanwon·
Respectfully, the Netflix analogy is the problem, not the pitch. Netflix won by being the best distribution layer for a commodity. The entire premise of modern telehealth is that medicine should work the same way: more drugs, faster, cheaper, with fewer gates. That framing is exactly how the category ended up looking less like healthcare and more like a pill mill with good design. Our patients at Healthspan don’t need a bigger GLP-1 catalog. They need someone looking at their labs, their training, their protein, their sleep and titrating an evidence-based protocol accordingly. That’s not a distribution problem. It’s a care problem. And this post is a pretty blunt admission of where the industry’s priorities actually sit. Adding more SKUs is easy. Looking after a patient comprehensively is hard. Most companies in the space have quietly picked the former and dressed it up as the latter.
andrewdudum@AndrewDudum

As of this morning, providers on our platform can now send prescriptions for Zepbound® vials and KwikPen®, as well as Foundayo™, to the LillyDirect® pharmacy and access self-pay pricing for our customers because of an expansion in our platform’s functionality. In many ways, today reminds me of Netflix’s early days, when everyone talked about whether they would have the latest blockbuster in their catalog. As if Netflix’s success depended on its ability to become the distribution channel for a single film. They were missing the forest for the trees: Netflix wasn’t just renting DVDs. It was changing consumer behavior by ruthlessly prioritizing choice and inventing new pathways to the things people wanted the most. By offering a full range of FDA-approved GLP-1s on our platform, we’re similarly giving our customers more choices through all the tools we have available – and we’ll continue to push here on behalf of everyone who depends on us for their care. Read more on how we’re making this possible, including important info, here: news.hims.com/newsroom/full-…

English
5
27
522
190.7K
Aman 🧙‍♂️ nag-retweet
Daniel Tawfik
Daniel Tawfik@dantawfik·
The incentive structure in telemedicine longevity is fundamentally broken. When revenue scales with prescription volume, the question shifts from "does this patient need this intervention?" to "can we convert this patient?" That's e-commerce with prescription requirements. It's not care. It's a pill mill. What's missing: Does this patient actually need this medication/supplement/peptide? What biological deficit are we addressing? How will we know if it's working? GLP-1 agonists and growth hormone secretagogues aren't supplements. They modulate core metabolic pathways. Many of the peptides shouldn't be taken chronically, for example. But the business models of these companies will treat them as chronically prescribed interventions for retention purposes. It's irresponsible. No baseline biomarkers or monitoring protocols. Care requires the opposite of what scales: decisions based on individual biology, narrower intervention selection, and continuous monitoring to validate response. That model is human-intensive. It requires clinicians who understand how these compounds map to aging mechanisms. That's hard. It takes work to have your own clinical team, who check-in with patients regularly, and has intrinsic interest in geroscience. And, yes, software can absolutely help clinical teams in measuring the responsiveness of interventions, but that's not what the current telemedicine offerings are doing in the pill mill model. We've spent the last year building the alternative at Healthspan: matching interventions to biological endpoints. It's also hard. We've hired clinicians who think about aging through the metabolic overdrive framework that underpins our philosophy. It's expensive, and it requires enormous logistical work to meet with patients regularly. It's easy to dole out meds. It's much harder to actually provide care.
Nikhil Krishnan@nikillinit

I get so many pitch decks now for peptide companies now and basically all of them 1) exclusively focus on their customer acquisition costs, their UGC/video content including AI generated marketing pipelines, and affiliate marketing strategy 2) talk about how fast their turnaround time is to patients and how broad their catalog of peptides are 3) do not talk at all about monitoring patients post prescription 4) they all say they work with the top suppliers to provide legitimacy but don't really have a clear methodology for how they're doing this (esp with so many steps between securing the in ingredient, to shipping, to compounding) I understand why peptides are popular - but I don't think having more companies who effectively are marketing/dropshipping companies while offloading liability and adverse events to the doctors is the right direction for healthcare

English
2
4
8
1.1K
Aman 🧙‍♂️ nag-retweet
Boyan Slat
Boyan Slat@BoyanSlat·
I have an irrational hatred toward this genre of books.
Boyan Slat tweet mediaBoyan Slat tweet media
English
774
4.1K
47.9K
2.5M
Steven Leflar
Steven Leflar@stevenleflar·
Still need a script to buy them right? My doctor wouldn’t even write me a script for testosterone even though my levels wouldn’t change from 240 even after 6 months of life changing changes. He cited old data that the FDA said isn’t true, but he’s going to write a script for pep’s?
English
62
1
58
55.6K
Secretary Kennedy
Secretary Kennedy@SecKennedy·
Today, we took long-overdue action to restore science, accountability, and the rule of law. In September 2023, the Biden FDA pushed a number of peptides into Category 2 — “Bulk Drug Substances that Raise Significant Safety Risks” — driving a dangerous black market that puts Americans at risk. Now, after nominators withdrew 12 peptides, the FDA will remove them from Category 2 and will bring them to PCAC at its next two meetings, beginning in July—where independent experts will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence. • BPC-157 • Thymosin beta-4 fragment (LKKTETQ) • Epitalon • GHK-Cu (injectable) • MOTS-c • DSIP (Emideltide) • Dihexa Acetate • Ibutamoren Mesylate • Melanotan II • KPV • Semax (heptapeptide) • Cathelicidin LL-37 This action begins to restore regulated access and will immediately begin shifting demand away from the black market. We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve.
English
1.1K
2.9K
22.9K
6.4M
Aman 🧙‍♂️ nag-retweet
Richard
Richard@gamray·
this is absolutely the greatest video of all time
FranceNews24@FranceNews24

📹 VIDÉO - #Insolite : Pendant la coupe des griffes, une marmotte semble avoir déjà accepté son destin… tandis que l’autre panique à chaque coup de coupe. Une scène aussi drôle que totalement théâtrale.

English
339
23.3K
248.5K
13M
Biohacker
Biohacker@biohacker·
The ultimate combos in health and fitness: > caffeine + l-theanine > sauna + l-citrulline > ground beef + rice > magnesium + thiamine What else am I missing?
English
74
112
2.1K
293.5K
Aman 🧙‍♂️ nag-retweet
animals with aura
animals with aura@Aniimalsauras·
The tears of the cat that found food after a long time:
English
465
11K
70K
2M
Aman 🧙‍♂️
Aman 🧙‍♂️@amanwon·
@ragecvlt Jung never wrote this no source exists. But the idea is real: when shadow work doesn’t happen, the defenses stop being adaptive and become identity. Worth saying accurately rather than inventing a citation for it.
English
0
0
1
361
Rage ❉
Rage ❉@ragecvlt·
Carl Jung wrote in 1933: The man who does not face his shadow by 35 does not improve. He calcifies. The defense becomes the personality.
English
95
842
7.7K
327.8K
Aman 🧙‍♂️ nag-retweet
DR22 Ω 🪬🎭
DR22 Ω 🪬🎭@DejaRu22·
Carl Jung on Basic factors making for happiness #3 is essential to awakening, btw I love people who carry with them a sense of wonder, and can enter into a state of awe by simply contemplating the existence of things. Essentially, those who actively possess with them, that which Blake put so eloquently: “To see a World in a Grain of Sand And a Heaven in a Wild Flower Hold Infinity in the palm of your hand And Eternity in an hour”
DR22 Ω 🪬🎭 tweet media
GIF
English
7
85
896
28.9K